A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3.BETA.-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS
5-cholesten-3, 25-diol, disulfate (25HCDS) has been found to be an authentic PPAR ³ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.5-콜레스텐-3β, 25-디올, 디설페이트 (25HCDS) 는 PPARγ 아고니스트 및 LXR 안타고니스트임이 밝혀졌고, 지방간, 염증성 장, 및 죽상동맥경화 질환을 제한 없이 포함하는, 지질 장애 및 염증성 질환의 치료에 사용된다.